All In MedTech

FDA Clearance Tracker · P010032-S165

Protege/Prodigy/Proclaim XR family of SCS IPGs, SCS EPG and SCS Percutaneous Permanent and Trial leads

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Nov 15, 2020 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Nov 15, 2020

Approved

Time to decision

178 days

Received May 21, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P010032-S165
Device name
Protege/Prodigy/Proclaim XR family of SCS IPGs, SCS EPG and SCS Percutaneous Permanent and Trial leads
Applicant location
Plano, TX
Received
May 21, 2020
Decided
Nov 15, 2020
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P010032

Device type

Device class
Class III

Every decision under product code LGW

FDA's approval statement

As written in FDA's record.

Approval for a change to the labeling which reflects an alternate lead implantation procedure for the Protege/Prodigy/Proclaim XR family of SCS systems.

Source documents

Other decisions for ABBOTT MEDICAL

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.